Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study.
Adiponectin and resistin are proteins that affect insulin resistance and atherosclerosis significantly. We investigated adiponectin and resistin concentrations as predictors of cardiovascular events in Korean patients with type 2 diabetes. The study in 2001 comprised 343 unrelated patients with type 2 diabetes (65+/-9.2 years old). They were followed up for 42 months. The baseline duration of diabetes, smoking status and history of cardiovascular diseases (CVD) were recorded. BMI, blood pressures, HbA1c, lipid profiles, ECG, creatinine and urine microalbumin were measured. Adiponectin and resistin were measured using enzyme-linked immunosorbent assays. The primary endpoint was defined as one of cardiovascular death, myocardial infarct, CABG, stroke, unstable angina or overt nephropathy. Thirty-eight patients (11.1%) experienced primary endpoint during the follow-up. After adjustment for age, sex, BMI, blood pressure and lipid status, participants in the lowest quartile of adiponectin levels compared with the highest had significantly increased risk of primary endpoint (relative risk=3.03; 95% CI 1.09-8.41; p=0.034). In contrast, resistin level had no influence on the risk of primary endpoint. A low level of adiponectin, not resistin, was a significant risk factor for the development of cardiovascular events in these Korean patients with type 2 diabetes.
Lim
Soo
S
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Koo
Bo Kyeong
BK
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Cho
Sun Wook
SW
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Kihara
Shinji
S
Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan.
Funahashi
Tohru
T
Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan.
Cho
Young Min
YM
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Kim
Seong Yeon
SY
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Lee
Hong Kyu
HK
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea.
Shimomura
Iichiro
I
Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Japan.
Park
Kyong Soo
KS
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Republic of Korea. Electronic address: kspark@snu.ac.kr.
D052242:Adiponectin / Q000097:blood; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000208:ethnology; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications / Q000208:ethnology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007723:Korea; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000208:ethnology; D016016:Proportional Hazards Models; D011446:Prospective Studies; D052243:Resistin / Q000097:blood*; D012307:Risk Factors; D020521:Stroke / Q000097:blood / Q000150:complications / Q000208:ethnology
C499918:ADIPOQ protein, human; D052242:Adiponectin; C499624:RETN protein, human; D052243:Resistin